No Detail Found!

HPLC Method Development and Validation of Atorvastatin Calcium in Bulk and Tablet Dossage Form.

Author(s)
Samina Alam Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Saima Saleem Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Safila Naveed Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Huma Dilshad Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Fatima Qamar Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Tanweer Alam Drug Regulatory Authority, Government of, Pakistan
Sidrah Khan Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Mariam Karim Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Amanullah Khan Drug Testing laboratory, Quetta, Health Department, Baluchistan,
Halima Sadia Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Abstract
Objective: The present work was aimed at the development of a simple, precise, rapid and selective RP-HPLC method for the estimation of Atorvastatin as API in both- bulk and pharmaceutical formulation. Methods:The method was carried out on HPLC a C18 column (25 cm x 4.6 mm) with mobile phase consisting of methanol:water:acetonitrile: orthophosphoric acid (85:10:4, 1 v/v) and pH was adjusted to 3.2 with flow rate of 1.8 ml per min.Detection was carried out at 247 nm. Besides, all parameters were found to be under required limits including limits of detection and limits of quantification.Further,the method was developed and validated; linearity, accuracy, precision, ruggedness and robustness, through an efficient HPLC technique in accordance with the ICH validation guidelines. Results:The results of all validated parameters - Linearity(r²= 0.999), Accuracy (101.5%) ,Precision, Ruggedness, Robustness, LOD (0.0008µg/ml) and LOQ (0.0002µg/ml) were found to be within required limits. Conclusion:As per above discussion the developed method is in accordance with ICH guidelines and can be easily used for Bulk and pharmaceutical formulation testing.
Publication Details
Page(s) 83-87
DOI DOI not available
Published Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 6, Issue: 1, Year: 2018

Request the full text from PASTIC

Keywords
HPLC, API and pharmaceutical formulation, method development
References
LaslettLJ,Alagona JrP,ClarkIII BA,Drozda JrJP,SaldivarF,WilsonSR,PoeC,HartM., .The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology,2012 Dec 60 S1 -49
AssmannG,Schulte H. The Prospective Cardiovascular, .Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease,1988 Dec 1 1713 -24
IstvanES,DeisenhoferJ, .Structural mechanism for statin inhibition of HMG-CoA reductase,Science. 2001 May 292 1160 -4
Athyros , V., 2004.The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study,Journal of clinical pathology 57 728 -734
Kim, 2008.Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process,International Journal of Pharmaceutics 359 211 -219
Shah , D., 2006.RP-HPLC determination of atorvastatin calcium and amlodipine besylate combination in tablets,Indian journal of pharmaceutical sciences 68 796 -
Kim,M.-S., 2008.Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process,European journal of pharmaceutics and biopharmaceutics 69 454 -465
Anwar , M., 2011.Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats,European Journal of Pharmaceutical Sciences 44 241 -249
Mukharya , A., 2011.Stable and Bio-equivalent Formulation of HMG-CoA reductase inhibitor: Atorvastatin Calcium,International Journal of Pharmaceutical Sciences Letters 2 12 -20
Sievens-Figueroa , L., 2012.Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications,International journal of pharmaceutics 423 496 -508
Aiyalu , R. and K.,Mani, 2012.HPTLC method development, validation, and stress degradation studies for atorvastatin and ezetimibe in multicomponent tablet dosage form,Medicinal Chemistry Research 21 1297 -1301
Attimarad , M., 2017.Capillary Electrophoresis Method Development for Simultaneous Determination of Atorvastatin and Ezetimibe from Solid Dosage Form,Journal of Young Pharmacists 9 120 -
Ertürk , S., 2003.An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets,Journal of pharmaceutical and biomedical analysis 33 1017 -1023
AshutoshKumar,S.,M.Debnath,J. SeshagiriRao, 2014.New Validated RP-HPLC Analytical Method for Simultaneous Estimation of Atorvastatin and Ezetimibe in Bulk Samples as Well in Tablet Dosage Forms by Using PDA Detector,Current drug discovery technologies 11 259 -270
Naveed , S.,SimpleUV, 2014.spectrophotometric assay of Atorvastatin API formulation and their comparative study,Global Journal of Medical Research -
RazaviB,AbdelmelekSB,SongW,O'SheaKE,CooperWJ, .Photochemical fate of atorvastatin (lipitor) in simulated natural waters,2011 Jan 1 625 -31
0

Citations

0

Downloads

29

Views